Hypothesis of COVID-19 Therapy with Sildenafil.
COVID-19
nitric oxide
sildenafil citrate
Journal
International journal of preventive medicine
ISSN: 2008-7802
Titre abrégé: Int J Prev Med
Pays: Iran
ID NLM: 101535380
Informations de publication
Date de publication:
2020
2020
Historique:
received:
12
05
2020
accepted:
10
06
2020
entrez:
17
9
2020
pubmed:
18
9
2020
medline:
18
9
2020
Statut:
epublish
Résumé
Bacterial or viral infections often cause acute and severe systemic inflammation, which affects the lungs lipopolysaccharide (LPS), a pathogenic component of the membrane of gram-negative bacteria, stimulates active innate immune cells, monocytes, macrophages to produce inducible nitric oxide synthase (iNOS). Excess production of this compound occurs in COVID-19 resulting in inflammatory cascade and thromboembolism. We intend to propose the use of sildenafil to reduce this production. The analysis of biochemical pathways shows that viral infection produces a high amount of nitric oxide (NO), with an acute inflammatory process. In the case of COVID-19 infection we verified that numerous biochemical processes activate a cascade of inflammatory processes through the activation of iNOS with uncontrolled generation of (NO). iNOS is the cause of damage to host cells with a consequent pulmonary thromboembolic lung phenomenon in a contest of interstitial pneumonia. This study proposes the use of sildenafil to counter the inflammatory cascade and thromboembolic episodes.
Identifiants
pubmed: 32939238
doi: 10.4103/ijpvm.IJPVM_258_20
pii: IJPVM-11-76
pmc: PMC7478270
doi:
Types de publication
Journal Article
Langues
eng
Pagination
76Informations de copyright
Copyright: © 2020 International Journal of Preventive Medicine.
Déclaration de conflit d'intérêts
There are no conflicts of interest.
Références
J Biol Chem. 2004 May 14;279(20):20767-74
pubmed: 14985344
Nitric Oxide. 2010 Dec 15;23(4):284-8
pubmed: 20804854
Handb Exp Pharmacol. 2011;(203):303-30
pubmed: 21484577
Front Immunol. 2020 Mar 10;11:414
pubmed: 32210977